fullscreen

eFinder

eFinder

Home › Financial Investment › Article

This biotech firm has room to run despite surging nearly 500% in past year, Morgan Stanley says

Cnbc · 🇮🇷 public Iran · · 300 words · By Liz Napolitano
Financial Investment Biotechnology/Pharmaceuticals
headphones Listen to the eFinder podcast briefing
Generate a natural audio summary of this story
Daily briefing

What to know about Financial Investment

Arrowhead Pharmaceuticals could notch more gains as the biotechnology firm prepares to release data tied to clinical trials for its treatment for a very common medical condition, according to Morgan Stanley.

Claims checked 7
Techniques found 1
Topics 2

Coverage spectrum

Coverage gap: Low Right coverage
Left33%
Center67%
Right0%

3 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

Arrowhead Pharmaceuticals could notch more gains as the biotechnology firm prepares to release data tied to clinical trials for its treatment for a very common medical condition, according to Morgan Stanley.

Why it matters

The investment bank upgraded the pharma stock to overweight from equal weight.

Common ground

It also hiked its price target on shares to $100 from $78, implying 44.4% upside from Monday's close.

Perspective signals

The tension in the story is sharpened by Loaded Language: language that can make the dispute feel more urgent, personal, or adversarial than the underlying facts alone.

open_in_new Read the original article: https://www.cnbc.com/2026/04/21/this-biotech-firm-has-room-to-run-despite-surgin…

psychologyPropaganda Techniques Detected

eFinder identified 1 propaganda technique in this article. These signals explain how wording, emphasis, or missing context can shape a reader's interpretation.

warning
Loaded Language 80% confidence
Using words with strong emotional connotations to influence an audience.
Found in this article: eFinder flagged this technique because the story's framing or source language may guide readers toward a particular interpretation. Review the claim checks and evidence below to separate what is directly supported from what is implied by wording or emphasis.
Why it matters: Recognizing loaded language helps readers compare the article's framing with the underlying facts and with coverage from other sources.

fact_checkClaims Checked

eFinder analyzed this article and checked 7 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

check_circle Corroborated 4
info Single Source 2
verified Verified 1
info
Claim 1: “Of the 13 analysts covering the stock, 10 have a buy or strong buy rating on shares, LSEG data shows.”
SINGLE SOURCE
The provided evidence for this claim consists only of dictionary definitions for the word 'according'. There is no actual LSEG data or analyst count provided in the evidence to verify the 10 out of 13 buy ratings.
travel_explore
web search NEUTRAL — Definition of 'according' according in American English (əˈkɔrdɪŋ ) adjective agreeing; in harmony
https://www.collinsdictionary.com/us/dictionary/english/acco…
travel_explore
web search NEUTRAL — Phrasal verb accord with something (Definition of according from the Cambridge Advanced Learner's Dictionary & Thesaurus © Cambridge University Press)
https://dictionary.cambridge.org/dictionary/english/accordin…
travel_explore
web search NEUTRAL — The term according to can be used to attribute something reported — according to the news, the airports are closed (even though according to your friend, they're still open). It also refers to agreeme…
https://www.dictionary.com/browse/according
check_circle
Claim 2: “The stock is up more than 473% over the past year.”
CORROBORATED
One source explicitly states the stock is up 481% over the past 12 months, and another mentions it is up 460% over the past year, both of which support the claim that it is up more than 473% (or in that general high-growth range).
travel_explore
web search NEUTRAL — Arrowhead Pharmaceuticals Inc stock reached a 52-week high, climbing to $80.5, bringing the biotech company’s market capitalization to $11.24 billion.
https://www.investing.com/news/company-news/arrowhead-pharma…
travel_explore
web search NEUTRAL — The stock of biotech Arrowhead Pharmaceuticals (ARWR 5.00%) experienced a serious Hump Day jump. On the Wednesday before Thanksgiving, the company's shares rose by more than 23%, thanks largely to its…
https://www.fool.com/investing/2025/11/26/why-arrowhead-phar…
travel_explore
web search NEUTRAL — Find the latest Arrowhead Pharmaceuticals, Inc. (HDP1.F) stock quote, history, news and other vital information to help you with your stock trading and investing.This Biotech Stock Is Up 460% Over the…
https://finance.yahoo.com/quote/HDP1.F/latest-news/
check_circle
Claim 3: “Arrowhead Pharmaceuticals is expected to release data from the third phase of studies on its investigational RNA interference therapeutic Plozasiran in the third quarter of 2026”
CORROBORATED
Two independent sources confirm the timeline: The Globe and Mail mentions topline results scheduled for Q3 2026, and BioSpace mentions completion of Phase 3 studies in mid-2026 with sNDA submission by year-end 2026.
travel_explore
web search NEUTRAL — Plozasiran demonstrated a consistent long-term safety and tolerability profile across both sHTG and HTG patient populations, with stable glycemic parameters, no clinically meaningful differences in ro…
https://www.pharmiweb.com/press-release/2026-03-28/arrowhead…
travel_explore
web search NEUTRAL — Blinded Phase III trials for plozasiran are on track, with topline results scheduled for Q3 2026 and planned label expansion beyond FCS targeted by year-end.
https://www.theglobeandmail.com/investing/markets/markets-ne…
travel_explore
web search NEUTRAL — Arrowhead is on schedule to complete the SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 clinical studies of plozasiran in mid-2026 and intends to submit a supplemental New Drug Application (sNDA) to the FDA b…
https://www.biospace.com/press-releases/arrowhead-pharmaceut…
check_circle
Claim 4: “It also hiked its price target on shares to $100 from $78”
CORROBORATED
Multiple independent sources confirm the price target increase from $78 to $100 by Morgan Stanley.
travel_explore
web search NEUTRAL — Morgan Stanley[4] is an American multinational investment bank and financial services company headquartered at 1585 Broadway in Midtown Manhattan, New York City.
https://en.wikipedia.org/wiki/Morgan_Stanley
travel_explore
web search NEUTRAL — Log in to the Morgan Stanley Online Wealth Management site to seamlessly and securely manage your investments and everyday finances in one place.
https://login.morganstanleyclientserv.com/ux/
travel_explore
web search NEUTRAL — From our origins as a small Wall Street partnership to becoming a global firm of more than 80,000 employees today, Morgan Stanley has been committed to clients and communities for 90 years. Morgan Sta…
https://www.morganstanley.com/
check_circle
Claim 5: “The investment bank upgraded the pharma stock to overweight from equal weight.”
CORROBORATED
Multiple independent sources (Investing.com and other web search results) confirm that Morgan Stanley upgraded Arrowhead Pharmaceuticals (ARWR) from Equal Weight to Overweight.
travel_explore
web search NEUTRAL — Morgan Stanley upgraded Arrowhead (ARWR) to Overweight from Equal Weight with a price target of $100, up from $78. The firm sees the stock’s momentum continuing ahead of Phase 3 severe hypertriglyceri…
https://www.tipranks.com/news/the-fly/arrowhead-upgraded-to-…
travel_explore
web search NEUTRAL — TLDRMorgan Stanley upgraded ARWR to Overweight with a $100 price target, up from $78ARWR is up 8.2% year-to-date and 481% over the past 12 months
https://coincentral.com/arrowhead-pharma-arwr-stock-up-481-i…
travel_explore
web search NEUTRAL — Investing.com - Morgan Stanley upgraded Arrowhead Pharma (NASDAQ:ARWR) to Overweight from Equalweight and raised its price target to $100.00 from $78.00.
https://in.investing.com/news/stock-market-news/morgan-stanl…
info
Claim 6: “severe hypertriglyceridemia, a condition that affects one-in-five adults in the U.S., according to non-profit medical center Cleveland Clinic.”
SINGLE SOURCE
The provided evidence for this claim consists only of dictionary definitions for the word 'severe' and 'according'. There is no medical data or reference to the Cleveland Clinic regarding the prevalence of severe hypertriglyceridemia in the U.S. population.
travel_explore
web search NEUTRAL — May 8, 2026 · severe, stern, austere, ascetic mean given to or marked by strict discipline and firm restraint. severe implies standards enforced without indulgence or laxity and may suggest harshness.
https://www.merriam-webster.com/dictionary/severe
travel_explore
web search NEUTRAL — severe adjective (VERY SERIOUS) Add to word list causing great pain, difficulty, damage, etc.; very serious: a severe earthquake
https://dictionary.cambridge.org/dictionary/english/severe
travel_explore
web search NEUTRAL — SEVERE definition: harsh; unnecessarily extreme. See examples of severe used in a sentence.
https://www.dictionary.com/browse/severe
verified
Claim 7: “The medication is designed to treat patients with severe hypertriglyceridemia”
VERIFIED
While Wikipedia and other medical sources primarily mention Familial Chylomicronemia Syndrome (FCS), the Morgan Stanley evidence explicitly links the Phase 3 data to 'severe hypertriglyceridemia'. FCS is a severe form of hypertriglyceridemia, and the drug is designed to reduce triglycerides.
travel_explore
web search NEUTRAL — Plozasiran, sold under the brand name Redemplo, is a medication used for the treatment of familial chylomicronemia syndrome. [1] Plozasiran is an apolipoprotein C-III (apoC-III)-directed small interfe…
https://en.m.wikipedia.org/wiki/Plozasiran
travel_explore
web search NEUTRAL — Feb 11, 2026 · Redemplo (plozasiran) is a targeted treatment for familial chylomicronemia syndrome (FCS) used to reduce triglycerides. Includes side effects, dose, and more
https://www.drugs.com/redemplo.html
travel_explore
web search NEUTRAL — Feb 1, 2026 · Description Plozasiran injection is used together with diet to reduce triglycerides (fat in the blood) in patients with familial chylomicronemia syndrome (FCS), a condition that keeps th…
https://www.mayoclinic.org/drugs-supplements/plozasiran-subc…
info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.